Kainos Medicine Inc
Kainos Medicine, Inc. engages in research and development of various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company's product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson's disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to tre… Read more
Kainos Medicine Inc (284620) - Net Assets
Latest net assets as of June 2025: ₩7.44 Billion KRW
Based on the latest financial reports, Kainos Medicine Inc (284620) has net assets worth ₩7.44 Billion KRW as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩11.62 Billion) and total liabilities (₩4.18 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩7.44 Billion |
| % of Total Assets | 63.99% |
| Annual Growth Rate | 9.44% |
| 5-Year Change | -85.53% |
| 10-Year Change | N/A |
| Growth Volatility | 332.06 |
Kainos Medicine Inc - Net Assets Trend (2017–2024)
This chart illustrates how Kainos Medicine Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Kainos Medicine Inc (2017–2024)
The table below shows the annual net assets of Kainos Medicine Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩1.79 Billion | -84.79% |
| 2023-12-31 | ₩11.75 Billion | -54.99% |
| 2022-12-31 | ₩26.11 Billion | +115.72% |
| 2021-12-31 | ₩12.10 Billion | -2.02% |
| 2020-12-31 | ₩12.35 Billion | +24.68% |
| 2019-12-31 | ₩9.91 Billion | +0.81% |
| 2018-12-31 | ₩9.83 Billion | +933.82% |
| 2017-12-31 | ₩950.59 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kainos Medicine Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12563985992000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩14.09 Billion | 788.10% |
| Other Components | ₩113.34 Billion | 6339.58% |
| Total Equity | ₩1.79 Billion | 100.00% |
Kainos Medicine Inc Competitors by Market Cap
The table below lists competitors of Kainos Medicine Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Southern Energy Corp
V:SOU
|
$17.12 Million |
|
Iz Hayvancilik Tarim ve Gida Sanayi Ticaret AS
IS:IZINV
|
$17.12 Million |
|
Generic Sweden publ AB
ST:GENI
|
$17.12 Million |
|
Allbirds Inc
NASDAQ:BIRD
|
$17.13 Million |
|
PharmaSGP Holding SE
F:PSG
|
$17.11 Million |
|
HeraMED Limited
F:1I4
|
$17.10 Million |
|
Prestige Wealth Inc.
NASDAQ:AURE
|
$17.10 Million |
|
TREJHARA SOLUTIONS LIMITED
NSE:TREJHARA
|
$17.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kainos Medicine Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 11,751,299,220 to 1,787,890,070, a change of -9,963,409,150 (-84.8%).
- Net loss of 12,190,154,740 reduced equity.
- Share repurchases of 1,643,455,940 reduced equity.
- New share issuances of 1,643,455,940 increased equity.
- Other factors increased equity by 2,226,745,590.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-12.19 Billion | -681.82% |
| Share Repurchases | ₩1.64 Billion | -91.92% |
| Share Issuances | ₩1.64 Billion | +91.92% |
| Other Changes | ₩2.23 Billion | +124.55% |
| Total Change | ₩- | -84.79% |
Book Value vs Market Value Analysis
This analysis compares Kainos Medicine Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 16.90x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.23x to 16.90x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩4783.54 | ₩1087.00 | x |
| 2018-12-31 | ₩8249.92 | ₩1087.00 | x |
| 2019-12-31 | ₩8317.15 | ₩1087.00 | x |
| 2020-12-31 | ₩533.75 | ₩1087.00 | x |
| 2021-12-31 | ₩497.63 | ₩1087.00 | x |
| 2022-12-31 | ₩935.25 | ₩1087.00 | x |
| 2023-12-31 | ₩420.94 | ₩1087.00 | x |
| 2024-12-31 | ₩64.30 | ₩1087.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kainos Medicine Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -681.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2064.85%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 6.01x
- Recent ROE (-681.82%) is below the historical average (-137.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -0.78% | 0.00% | 0.00x | 1.78x | ₩-102.46 Million |
| 2018 | 0.40% | 0.00% | 0.00x | 1.08x | ₩-943.79 Million |
| 2019 | 0.81% | 0.00% | 0.00x | 1.08x | ₩-910.67 Million |
| 2020 | -92.67% | 0.00% | 0.00x | 2.82x | ₩-12.68 Billion |
| 2021 | -133.94% | -975.18% | 0.04x | 3.47x | ₩-17.42 Billion |
| 2022 | -60.83% | -12213.85% | 0.00x | 1.49x | ₩-18.49 Billion |
| 2023 | -129.65% | -5699.35% | 0.01x | 1.79x | ₩-16.41 Billion |
| 2024 | -681.82% | -2064.85% | 0.05x | 6.01x | ₩-12.37 Billion |
Industry Comparison
This section compares Kainos Medicine Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kainos Medicine Inc (284620) | ₩7.44 Billion | -0.78% | 0.56x | $17.12 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |